New Study Highlights Benefits of Shingles Vaccine
A recent study from Case Western Reserve University suggests that getting the shingles vaccine might offer protective benefits beyond preventing shingles, a painful rash caused by the reactivation of the varicella-zoster virus.
The research presented at the IDWEEK 2025 conference in Atlanta shows a possible connection between the shingles vaccine and a lower risk of developing vascular dementia, as well as reduced chances of serious cardiovascular issues and mortality for individuals aged 50 and older.
The study analyzed health records of 174,000 adults across the U.S., tracking those who received the vaccine for a period ranging from three months to seven years. Findings revealed that those vaccinated had about half the risk of developing vascular dementia. Additionally, they experienced a 25% lower risk of heart attack or stroke, a 27% lower risk of blood clots, and a 21% lower risk of death.
The presenting author, Dr. Ali Dehghani, emphasized the vaccine’s potential to lower these health risks, especially for individuals already at higher risk for heart problems.
Shingles, characterized by a red, blistery rash, affects about one in three Americans. The virus that causes it remains dormant after chickenpox and can reactivate later in life.
Dr. Dehghani pointed out that shingles is not just a benign rash; it can lead to serious heart and brain health issues. These new findings add to previous research suggesting that the shingles vaccine not only prevents the painful illness but may also protect against related health complications.
Dr. Aaron Glatt, a spokesperson for the Infectious Diseases Society of America, commented on the study’s implications, noting that it supports prior evidence that the shingles vaccine could offer broader health benefits, including reduced risks of dementia.
While the results are promising, Dr. Glatt also stated that more research is needed to definitively prove that these benefits stem from the shingles vaccine. Possible reasons for this association could include reduced inflammation.
The Centers for Disease Control and Prevention currently recommends that adults aged 50 and older receive two doses of the recombinant zoster vaccine to prevent shingles and its complications.
In summary, this study suggests that the shingles vaccine might play a vital role in enhancing overall health, encouraging individuals to consider vaccination as a means to protect themselves from a range of potential health issues.
